Highest development stage: Preclinical

Development status: Active (as of 2022)

Gram-negative activity

Mechanism of Action/Target pathogen: Inhibits PBP2 and is unaffected by β-lactamase mediated resistance. Active against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii

Additional information: Synthetic compound. Inhibitor of serine Beta-Lactamases